VIVALDI: Valdoxan improves depressive symptoms and normalises circadian rhythms - an observational prospective study.

Trial Profile

VIVALDI: Valdoxan improves depressive symptoms and normalises circadian rhythms - an observational prospective study.

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Jun 2014

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms VIVALDI
  • Sponsors Servier
  • Most Recent Events

    • 30 Oct 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 27 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top